Pharmacogenomics in the era of personalised medicine.
作者信息
White Cassandra, Scott Rodney, Paul Christine L, Ackland Stephen P
机构信息
Maitland Hospital, Maitland, NSW.
University of Newcastle, Newcastle, NSW.
出版信息
Med J Aust. 2022 Nov 21;217(10):510-513. doi: 10.5694/mja2.51759. Epub 2022 Oct 18.
Abstract
摘要
相似文献
1
Pharmacogenomics in the era of personalised medicine.个性化医疗时代的药物基因组学。
Med J Aust. 2022 Nov 21;217(10):510-513. doi: 10.5694/mja2.51759. Epub 2022 Oct 18.
2
The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress.第六届欧洲药物基因组学和个体化治疗学会大会。
Pharmacogenomics. 2023 Apr;24(5):243-246. doi: 10.2217/pgs-2023-0013. Epub 2023 Apr 4.
3
Pharmacology Focus: Pharmacogenomics: Gene-directed Prescribing in the Era of Personalized Medicine.药理学聚焦：药物基因组学：个性化医疗时代的基因导向处方
S D Med. 2019 Jun;72(6):280-281.
4
New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics.癌症中针对种族的个性化医疗新视角：群体药物基因组学与药物计量学
Drug Metab Pers Ther. 2018 Jun 27;33(2):61-64. doi: 10.1515/dmpt-2018-0008.
5
Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT).瑞士药物基因组学与个性化治疗小组（SPT）的成立。
Drug Metab Pers Ther. 2017 Dec 20;32(4):173-174. doi: 10.1515/dmpt-2017-0033.
6
The Daniel K. Inouye College of Pharmacy Scripts: Precision Medicine Through the Use of Pharmacogenomics: Current Status and Barriers to Implementation.丹尼尔·K·伊努耶药学院文稿：通过药物基因组学实现精准医学：现状与实施障碍
Hawaii J Med Public Health. 2017 Sep;76(9):265-269.
7
4th ESPT summer school: precision medicine and personalised health.第四届欧洲精准肿瘤学会暑期学校：精准医学与个性化健康
Pharmacogenomics. 2019 May;20(7):471-474. doi: 10.2217/pgs-2019-0008.
8
Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care.推进药物遗传学和药物基因组学在临床护理中的应用。
Pathology. 2013 Jun;45(4):357-70. doi: 10.1097/PAT.0b013e328360b66e.
9
Pharmacogenomics and patient care: one size does not fit all.药物基因组学与患者护理：一概而论并不合适。
Sci Transl Med. 2012 Sep 26;4(153):153ps18. doi: 10.1126/scitranslmed.3003471.
10
Report on the pharmacogenomics and personalized medicine 2011 conference: part 1.2011 年药物基因组学与个性化医学会议报告：第 1 部分。
Pharmacogenomics. 2012 Jan;13(2):141-5. doi: 10.2217/pgs.11.180.
引用本文的文献
1
Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives.变革个性化医疗：与多组学数据生成的协同作用、主要障碍及未来展望
Biomedicines. 2024 Nov 30;12(12):2750. doi: 10.3390/biomedicines12122750.
2
The needs and gaps in pharmacogenomics knowledge and education among healthcare professionals in Malaysia: A multisite Delphi study.马来西亚医疗保健专业人员在药物基因组学知识和教育方面的需求和差距：一项多地点德尔菲研究。
Clin Transl Sci. 2024 Nov;17(11):e70057. doi: 10.1111/cts.70057.
3
Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review.药物基因组学对心血管治疗的变革：一篇综述
Health Sci Rep. 2024 Oct 20;7(10):e70139. doi: 10.1002/hsr2.70139. eCollection 2024 Oct.
4
Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response.受体药理学基因组学：解析遗传对药物反应的影响。
Int J Mol Sci. 2024 Aug 29;25(17):9371. doi: 10.3390/ijms25179371.
5
Commentary: The pharmacogenomic landscape of an Indigenous Australian population.评论：澳大利亚原住民群体的药物基因组学概况。
Front Pharmacol. 2024 May 15;15:1373056. doi: 10.3389/fphar.2024.1373056. eCollection 2024.
6
Evaluation of Genetic Variant and Its Lack of Association with Valproic Acid Plasma Concentrations Among Zhuang and Han Schizophrenia Patients in Guangxi.广西壮族和汉族精神分裂症患者基因变异及其与丙戊酸血药浓度的相关性评估
Pharmgenomics Pers Med. 2024 May 14;17:225-236. doi: 10.2147/PGPM.S457805. eCollection 2024.
7
Mining local exome and HLA data to characterize pharmacogenetic variants in Saudi Arabia.挖掘本地外显子组和 HLA 数据，以鉴定沙特阿拉伯的药物遗传学变异。
Hum Genet. 2024 Feb;143(2):125-136. doi: 10.1007/s00439-023-02628-z. Epub 2023 Dec 30.
8
Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review.肿瘤药理学基因组学中医疗保健专业人员和消费者的知识、态度、观点和教育需求：系统评价。
Clin Transl Sci. 2023 Dec;16(12):2467-2482. doi: 10.1111/cts.13672. Epub 2023 Nov 22.
9
Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper.优化患有多种疾病和多种药物治疗的老年患者的药物治疗和减药策略：EuGMS 药理学工作组关于立场文件的建议。
Eur Geriatr Med. 2023 Dec;14(6):1195-1209. doi: 10.1007/s41999-023-00872-0. Epub 2023 Oct 9.
本文引用的文献
1
Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.瑞士癌症患者中预防早发性氟嘧啶相关毒性的药物遗传学检测的临床应用
Front Pharmacol. 2022 May 18;13:885259. doi: 10.3389/fphar.2022.885259. eCollection 2022.
2
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.二氢嘧啶脱氢酶缺陷与前瞻性 DPYD 基因分型的实施。
Clin Pharmacol Ther. 2022 Oct;112(4):791-802. doi: 10.1002/cpt.2667. Epub 2022 Jun 12.
3
Ethnic Diversity of DPD Activity and the Gene: Review of the Literature.二氢嘧啶脱氢酶活性及基因的种族多样性：文献综述
Pharmgenomics Pers Med. 2021 Dec 9;14:1603-1617. doi: 10.2147/PGPM.S337147. eCollection 2021.
4
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.氟嘧啶类化疗：瑞士药物基因组学和个体化治疗小组的 DPYD 基因分型和治疗药物监测建议。
Swiss Med Wkly. 2020 Nov 24;150:w20375. doi: 10.4414/smw.2020.20375. eCollection 2020 Nov 16.
5
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice.阿姆斯特丹大学医学中心在使用氟嘧啶治疗前进行二氢嘧啶脱氢酶（DPD）检测：当前药物遗传学实践的评估
Front Pharmacol. 2020 Jan 28;10:1609. doi: 10.3389/fphar.2019.01609. eCollection 2019.
6
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.荷兰药物遗传学工作组（DPWG）关于 DPYD 和氟嘧啶类药物基因-药物相互作用的指南。
Eur J Hum Genet. 2020 Apr;28(4):508-517. doi: 10.1038/s41431-019-0540-0. Epub 2019 Nov 19.
7
Pharmacogenomics in general practice: The time has come.一般实践中的药物基因组学：时机已到。
Aust J Gen Pract. 2019 Mar;48(3):100-105. doi: 10.31128/AJGP-10-18-4733.
8
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.氟嘧啶类抗肿瘤治疗中 upfront DPYD 基因型指导剂量个体化的成本分析。
Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.
9
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.携带 DPYD*2A 变异的患者中低剂量氟嘧啶治疗的有效性和安全性：一项配对分析。
Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.
10
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.基于 DPYD 基因型的氟嘧啶类药物个体化剂量在癌症患者中的应用：一项前瞻性安全性分析。
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
Zotero 插件